Skip to main content

Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026

Interventional Radiology Imaging Market

The global Interventional Radiology Imaging market was valued at USD 10,000 Million in 2025 and is projected to reach USD 18,771.37 Million by 2035, expanding at a CAGR of 6.5% over the forecast period. Growth is driven by increasing adoption of minimally invasive procedures and advancements in imaging technologies. The market remains concentrated in regions with robust healthcare infrastructure and regulatory support.

Demand is further supported by rising prevalence of chronic diseases and the need for precise diagnostic and therapeutic interventions.

Report scope & segmentation

Interventional Radiology Imaging Market is Segmented by Product (MRI Systems, Ultrasound Imaging Systems, CT Scanners, Angiography Systems, Fluoroscopy Systems, Biopsy Devices, and Other Products), Application (Cardiology, Urology and Nephrology, Oncology, Gastroenterology, and Other Applications), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers) and by Region Global Trends and Forecast From 2023 To 2029

Market size

Growth trajectory through 2035

$10.00 Bn Base 2025
↑ 6.50% CAGR 2025–2035
$18.77 Bn Forecast 2035

Interventional Radiology Imaging Market · Market size 2025–2035

Base year 2025 · Forecast 2035 · USD Billion

Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.

What this shows

The Interventional Radiology Imaging Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.

What's new in this edition

Here's what changed

This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.

Recent developments tracked

  1. 2026 April 2026
    • [Additional data pending].
  2. 2026 March 2026
    • [Additional data pending].
  3. 2026 February 2026
    • [Additional data pending].

Emerging opportunities added

  • Integration of artificial intelligence (AI) and machine learning AI-driven enhancements in image interpretation and workflow automation present opportunities to improve diagnostic efficiency and reduce operational costs.
  • Expansion into new clinical applications Growth potential exists in areas such as sports medicine, rheumatology, and preventive diagnostics, where imaging technologies are increasingly utilized beyond traditional fields.

Executive snapshot

The four things that matter

A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.

Market size · 2025–2035

$18.77 Bn

forecast for 2035

2025 base
$10.00 Bn
CAGR
6.50%
Expansion
1.9×

Market shape

MRI Systems

top segment · 40.7% share

Leading region
North America
Top-5 concentration
Low to medium · ~42%

Forces at play

Rising prevalence of chronic diseases

▲ top tailwind

▼ headwind
High capital expenditure and operational costs
Named players
15 profiled
Growth peak
2027–2031

Latest development

2026

April 2026: [Additional data pending]

+2 more tracked in this edition

Report scope

What this report answers

The specific decisions and questions covered in the 70-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.

  • How big is the Interventional Radiology Imaging Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
  • Which of MRI Systems, Ultrasound Imaging Systems, CT Scanners and other tracked segments holds the largest share, and how do the growth rates diverge?
  • How is demand distributed across Cardiology, Urology, Nephrology applications, and which application is scaling fastest?
  • How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
  • Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
  • What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by High capital expenditure and operational costs), with quantified CAGR impact?
  • What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
  • Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?

Market dynamics

Why the number moves this way

The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.

Growth drivers

Pulling the market up

  • Rising prevalence of chronic diseases The increasing burden of cardiovascular, oncological, and neurological conditions necessitates precise diagnostic and therapeutic interventions, driving demand for interventional radiology imaging systems.
  • Advancements in imaging technologies Innovations such as high-resolution MRI, multi-slice CT, and hybrid imaging systems improve procedural accuracy and patient outcomes, supporting market expansion.
  • Growth of minimally invasive procedures The shift toward less invasive treatments reduces recovery times and procedural risks, increasing the adoption of interventional radiology techniques across clinical settings.

Restraints

Holding it back

  • High capital expenditure and operational costs The upfront investment required for advanced imaging systems and associated infrastructure limits market penetration in lower-income regions.
  • Stringent regulatory requirements Compliance with evolving regulatory frameworks for medical devices and imaging systems can delay product launches and increase operational complexity.
  • Limited reimbursement policies in emerging markets Inconsistent reimbursement structures in certain geographies constrain market growth by reducing affordability for healthcare providers and patients.

Impact analysis

Quantified drivers & restraints

Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.

Driver% Impact on CAGRGeographic RelevanceImpact Timeline
Rising prevalence of chronic diseases +2.9% Global 2025–2035
Advancements in imaging technologies +1.8% Global 2025–2035
Growth of minimally invasive procedures +1.4% Global 2025–2035

Restraints impact analysis

Restraint% Impact on CAGRGeographic RelevanceImpact Timeline
High capital expenditure and operational costs −1.2% Global 2025–2029
Stringent regulatory requirements −0.8% Global 2025–2029
Limited reimbursement policies in emerging markets −0.6% Global 2025–2029

The market is segmented by product type, application, end-use, and region. Product categories include MRI systems, ultrasound imaging systems, CT scanners, angiography systems, fluoroscopy systems, biopsy devices, and other products. Applications span cardiology, urology and nephrology, oncology, gastroenterology, and other medical specialties. End-use segments comprise hospitals, clinics, and ambulatory surgical centers.

Revenue share by type · 2025 base year

% OF $10.00 BN INTERVENTIONAL RADIOLOGY IMAGING MARKET · 4 TYPES COVERED

Each slice = that type's share of the total $10.00 Bn Interventional Radiology Imaging Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.

By type

  1. MRI Systems

  2. Ultrasound Imaging Systems

  3. CT Scanners

  4. Angiography Systems

  5. Fluoroscopy Systems

  6. Biopsy Devices

By application

  1. Cardiology

  2. Urology

  3. Nephrology

  4. Oncology

  5. Gastroenterology

Geography

Regional market share

Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.

Regional share · 2025

SHARE OF $10.00 BN BASE MARKET

Bars sized to relative regional share. Leader region highlighted in gold.

What this shows

North America leads regional demand at ~48.0% in 2025. The region is a leading market due to high healthcare expenditure, advanced infrastructure, and strong regulatory support for medical device innovation

Per-region detail

  • North America

    The region is a leading market due to high healthcare expenditure, advanced infrastructure, and strong regulatory support for medical device innovation

  • Europe

    Growth is driven by increasing adoption of minimally invasive procedures and investments in digital health integration across healthcare systems

  • Asia-Pacific

    The market is expanding rapidly due to rising healthcare access, growing prevalence of chronic diseases, and increasing healthcare investments in emerging economies

  • Latin America

    Market growth is constrained by economic disparities and limited healthcare funding, though demand for cost-effective imaging solutions is rising

  • Middle East & Africa

    The market remains underdeveloped relative to other regions, with growth potential tied to improving healthcare infrastructure and regulatory frameworks

Competitive landscape

Who's competing, and how

The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.

The market exhibits moderate concentration, with a mix of multinational corporations and specialized imaging technology providers competing for market share. Competitive dynamics are shaped by innovation in imaging modalities, strategic partnerships, and regional distribution networks.

Concentration snapshot

Top 5 players control ~35–50% of the market

Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.

Top 5 players Rest of market
~43%
~58%

Competitive tiers

Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.

Tier 1 · Leaders

3companies

Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.

Tier 2 · Challengers

5companies

Regional strongholds, focused portfolio, actively expanding via M&A or capacity.

Tier 3 · Emerging

7companies

Niche or early-stage, differentiated technology or early-mover positioning.

Named players covered

Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.

  • Thermo Fisher Scientific

    Leading player · Full profile in the report

    Rank 01
    Share est. ~16%
    Revenue $■■■M
    HQ ■■■
  • Danaher Corporation

    Profiled · Full detail in the report

    Rank 02
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Roche Diagnostics

    Profiled · Full detail in the report

    Rank 03
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Abbott Diagnostics

    Profiled · Full detail in the report

    Rank 04
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Siemens Healthineers

    Profiled · Full detail in the report

    Rank 05
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Bio-Rad Laboratories

    Profiled · Full detail in the report

    Rank 06
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • QIAGEN N.V

    Profiled · Full detail in the report

    Rank 07
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Hologic Inc

    Profiled · Full detail in the report

    Rank 08
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■

+ 7 more player profiles in the full report.

Unlock the full competitive landscape

Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.

Download sample

Regulatory landscape

Policy and standards affecting the forecast

Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.

  1. United States

    FDA · IRA drug pricing · CMS

    FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.

  2. European Union

    EMA · HTA Reg · GDPR-health

    EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.

  3. China / APAC

    NMPA · VBP · NRDL

    NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.

  4. Global standards

    ICH · WHO · Pharmacopoeia

    ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.

Purchase options

License this report

All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.

Individual

Single user

$3,499

  • 1 named user, non-transferable
  • Full PDF + Excel data pack
  • 1 hour analyst clarification call
Buy Now Request sample
Enterprise

Corporate

$5,499

  • Unlimited users org-wide
  • Full PDF + Excel data pack
  • 4 hours analyst time
  • Presentation-ready deck
Buy Now Request sample

Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.

How buying works

  1. 01 Select a license — your enquiry reaches the desk lead within one business day.
  2. 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
  3. 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.

Payment methods accepted

  • PayPalGlobal
  • RazorpayCards · UPI · Netbanking
  • Visa · Mastercard · AmexVia gateway
  • Wire transferUSD · EUR · INR · GBP
  • Corporate PONet-30 on approval

Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.

Methodology

How we built this estimate

Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.

  1. Primary research

    Interviews · surveys

    Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.

  2. Secondary research

    Filings · associations · databases

    Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.

  3. Data triangulation

    Three independent paths

    Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.

  4. Analyst review

    Senior sign-off

    Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.

Frequently asked questions

Common questions about this report

  • • What is the worth of global Interventional radiology imaging market?
    The Interventional radiology imaging market reached USD 23.18 Billion in 2020 and is expected to grow at a CAGR of more than 7% through 2029, owing to the increasing development in the cardiology application.
  • • What are the upcoming trends of Interventional radiology imaging market, globally?
    The upcoming trend in the Interventional radiology imaging market is an opportunity for market growth in enterprise applications.
  • • What is the CAGR of Interventional radiology imaging market?
    The global Interventional radiology imaging market registered a CAGR of 7% from 2022 to 2029.
  • • Which are the top companies to hold the market share in Interventional radiology imaging market?
    Key players profiled in the report include General Electric, Koninklijke Philips N.V., Carestream Health, ESAOTE SPA, Hitachi, Ltd., Hologic, Inc., Shimadzu Corporation, Siemens Healthcare GmbH, Canon Medical Systems Corporation, Samsung Medison Co., Ltd., Medtronic Plc, Agfa-Gevaert Group, Teleflex Incorporated, Analogic Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Trivitron Healthcare, Stryker Corporation, Olympus Corporation, Toshiba Medical Systems.
  • • Which is the largest regional market for Interventional radiology imaging market?
    North America is expected to have the largest market share of 37% in the global interventional radiology devices market out of all regions. This is due to an Increasing patient pool in the region and the rising need for improvement in the quality of patient care will increase the product demand.